LABORATOIRE HRA-PHARMA;The United States of America, as represented by the Secretary, Department of Health and Human Services
发明人:
Andre Ulmann,Erin Gainer,Henri Camille Mathe,Diana Blithe,Lynnette Nieman
申请号：
US15016845
公开号：
US10159681B2
申请日:
2016.02.05
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
